VENOUS THROMBOEMBOLISM (VTE) is a common disease, with an average annual incidence of over 1 per 1000.1 Venous thromboembolism also is a potentially lethal disease, mostly owing to pulmonary embolism (PE). Almost one quarter of all PE cases present as essentially sudden death, with a 1-week survival of only 71%.2 Patients with deep vein thrombosis (DVT) often experience serious and costly long-term complications. Almost 30% of patients develop serious venous stasis syndrome within 10 years3,4 at an estimated cost of over $4000 per episode in 1997 dollars.5 To improve survival and prevent complications, the incidence of VTE must be reduced.
Heit JA. The Potential Role of Fondaparinux as Venous Thromboembolism Prophylaxis After Total Hip or Knee Replacement or Hip Fracture Surgery. Arch Intern Med. 2002;162(16):1806–1808. doi:10.1001/archinte.162.16.1806
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.